Abstract
This poster presentation will identify the risk of metabolic syndrome at baseline in a community-based pragmatic clinical trial of youth with bipolar spectrum disorder who are treated with second-generation antipsychotic (SGA) drugs. In addition, it will highlight the challenges of treating these youth (ie, completion of recommended laboratories) within a pragmatic clinical trial design.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of the American Academy of Child & Adolescent Psychiatry
Paper Title
Journal
Date
